The causes of lone AF remain unclear. Astute investigators have recognized familial occurrence despite low penetrance, and standard genetic techniques have led to the identification of several chromosomal loci and genes in which mutations can cause dominantly inherited AF. These include genes encoding myocardial potassium (KCNQ1, KCNA5, KCNE5, KCNJ2, and KCNE2) and sodium (SCN5A, SCN1B, SCN2B, and SCN3B) channels, potassium-adenosine triphosphate channels (ABCC9), nucleoporin-155 (NUP155), gap junction protein connexin 40 (GJA5), and atrial natriuretic peptide (NPPA) (6 -17) . Single-nucleotide polymorphisms (SNPs) on chromosome 4q25 were initially recognized in association with AF as part of the groundbreaking genomewide association studies that were performed in Iceland (18) . This association was replicated in several other cohorts with European ancestry as well as among Han Chinese patients with AF (18, 19) . The rs2200733-T allele carries an odds ratio for AF of 1.90 in combined analysis of several cohorts (p ϭ 3.3 ϫ 10
Ϫ13
) (19) . In this issue of the Journal, Ritchie et al. (20) from Vanderbilt University use a robust AF registry to investigate the genetic basis and penetrance of familial AF. In a cohort with lone AF, deoxyribonucleic acid (DNA) sequence analysis was performed for KCNQ1 and KCNA5 in 231 probands, NKX2-5 in 160, SCN5A in 118, and NPPA in 98. The investigators identified 11 families in which AF was present in Ն2 people who also shared a possible DNA mutation in 1 of these genes. The penetrance of AF in family members who carried the putative mutation was low and age dependent, consistent with prior reports (21) . Addition of the chromosome 4q25 SNP genotypes helped predict whether the carriers of these rare variants would develop AF.
Their findings are interesting but should be considered with some caution. First, are these rare DNA variants truly responsible for familial AF in these families? For instance, SCN5A p.L461V was found in 3 affected relatives in family AF242. Another group found this variant in a patient with sudden cardiac death, yet it failed to segregate with disease in the family (22) . The National Heart, Lung, and Blood Institute's Exome Variant Server (23) indicates a minor allele frequency of 0.89% in African Americans. Does that exclude it as responsible or functional? It certainly does not; yet functional evidence of its pathogenicity would help. Similarly, p.A572D in SCN5A, p.insAP54-56 in KCNQ1, and p.S64L in NPPA have all been seen in "controls." Functional studies of p.A572D demonstrated no effect unless the minor allele of a more common SCN5A variant, p.H558R, was also present (24) . These 2 SCN5A variants appear to be linked, and R558 (the minor allele) is also associated with AF (25) . At this point, p.A572D in SCN5A should be considered a rare polymorphism whose significance is unknown.
Who constitutes an appropriate negative control for an AF genetics study? Even carefully phenotyped controls without known paroxysms of prior AF may experience it later in life. For a disorder as common and complex as AF, we must keep in mind that contributory DNA variants probably occur with similar prevalence as AF. Pathogenicity simply cannot be determined by the rarity of a novel DNA variant or its cosegregation with AF in a small family. A variant such as NPPA p.A117V may seem like a minor change, because alanine is very similar to valine, but the C-to-T alteration in DNA might create cryptic splicing, with introduction of a GT sequence that could create a 5= splice donor. Once again, in the absence of functional data, the significance of these rare DNA variants remains unknown. From the Center for Inherited Heart Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. Dr. Judge has reported that he has no relationships relevant to the contents of this paper to disclose.
How do the chromosome 4q25 noncoding SNPs influence the development of AF? This also is an area of active investigation without clear answers today. These seemingly innocuous variations in intronic DNA sequences do not directly alter the amino acid sequence in any protein, but they occur in a highly conserved locus among many species. This suggests that they act as markers of nearby functional or regulatory elements (26) . PITX2 is the closest gene in proximity, and it encodes a homeobox protein that is expressed in developing myocardium, perhaps contributing to cardiomyoblast proliferation and myogenesis (27) . This gene is widely expressed in the developing embryo, contributing to left-right signaling (28) . Dominant mutations in this gene result in Axenfeld-Rieger syndrome, which is characterized by ocular, craniofacial, dental, and periumbilical abnormalities (28) . But the interval between the SNP with the strongest association to AF (rs2200733) and PITX2 is 146,890 base pairs, on the basis of the latest annotation of the human genome. Despite overwhelming evidence of a modest effect on AF mediated by this chromosomal locus, the mechanism remains a mystery at this point.
Since completion of the first whole human genome sequencing more than a decade ago, improvements in technology have dramatically accelerated the efficiency with which DNA analysis can be performed. Early (MaxamGilbert) DNA sequencing with isotope-labeled fragments of DNA was replaced by dideoxy (Sanger) sequencing, followed by chip-based platforms and subsequently "nextgeneration" technologies. These include polony sequencing, pyrosequencing, sequencing by ligation, and nonoptical ion sensing techniques (29) . Today, robust sequencing of enormous amounts of DNA can be performed at a fraction of the costs required just a few years ago. Next-generation sequencing technologies are now used in many clinical (Clinical Laboratory Improvement Amendments-certified) laboratories, and cardiovascular diseases in particular are deemed ripe for the expanding use of genetic testing in clinical practice.
Currently, approximately 50% of the genes in which mutations cause familial AF are available for clinical genetic testing in the U.S., and that list will certainly grow. Genotyping for a panel of common SNPs, including the chromosome 4q25 rs2200733 and rs10033464 makers, is also clinically available. Yet recently published guidelines classify genetic testing for AF as "Class III (is not indicated/ recommended)," specifically also commenting on SNP genotyping as "not indicated at this time based on the limited outcome data currently available" (30) . Acknowledging that AF genetics is complex and that there is no role for genetic testing for most people with AF, Ritchie et al. (20) also suggest that a case can be made for genetic testing in the setting of early-onset familial or lone AF. Such an optimistic perspective regarding the clinical application of genetic testing should not be taken as a consensus opinion, because the risks of misinterpretation are high, and the therapeutic value in the context of such uncertainly seems quite low.
Looking toward the future, costs for genetic analysis will continue to decline. Better recognition of the pathogenic effects of both rare and common DNA variants will improve our ability to interpret such sequencing, and the use of genetic testing will continue to grow. As cardiologists, we must be prepared for the rapidly expanding role of genetic analysis in clinical practice, yet we should remain skeptical about its use for complex disorders, such as AF, until larger studies demonstrate clear utility.
